Previous Article | Next Article ![]()
Clinical Microbiology Reviews, Oct 1996, 532-562, Vol 9, No. 4
DR Lucey, M Clerici and GM Shearer
In the mid-1980s, Mosmann, Coffman, and their colleagues discovered that
murine CD4+ helper T-cell clones could be distinguished by the cytokines
they synthesized. The isolation of human Th1 and Th2 clones by Romagnani
and coworkers in the early 1990s has led to a large number of reports on
the effects of Th1 and Th2 on the human immune system. More recently, cells
other than CD4+ T cells, including CD8+ T cells, monocytes, NK cells, B
cells, eosinophils, mast cells, basophils, and other cells, have been shown
to be capable of producing "Th1" and "Th2" cytokines. In this review, we
examine the literature on human diseases, using the nomenclature of type 1
(Th1-like) and type 2 (Th2-like) cytokines, which includes all cell types
producing these cytokines rather than only CD4+ T cells. Type 1 cytokines
include interleukin-2 (IL-2), gamma interferon, IL-12 and tumor necrosis
factor beta, while type 2 cytokines include IL-4, IL-5, IL-6, IL-10, and
IL-13. In general, type 1 cytokines favor the development of a strong
cellular immune response whereas type 2 cytokines favor a strong humoral
immune response. Some of these type 1 and type 2 cytokines are cross-
regulatory. For example, gamma interferon and IL-12 decrease the levels of
type 2 cytokines whereas IL-4 and IL-10 decrease the levels of type 1
cytokines. We use this cytokine perspective to examine human diseases
including infections due to viruses, bacteria, parasites, and fungi, as
well as selected neoplastic, atopic, rheumatologic, autoimmune, and
idiopathic-inflammatory conditions. Clinically, type 1 cytokine-
predominant responses should be suspected in any delayed-type
hypersensitivity-like granulomatous reactions and in infections with
intracellular pathogens, whereas conditions involving
hypergammaglobulinemia, increased immunoglobulin E levels, and/or
eosinophilia are suggestive of type 2 cytokine-predominant conditions. If
this immunologic concept is relevant to human diseases, the potential
exists for novel cytokine-based therapies and novel cytokine- directed
preventive vaccines for such diseases.
Copyright © 1996 by the American Society for Microbiology. All rights reserved.
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Experimental Immunology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»